Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOESTRIN 24 FE vs ESTROSTEP 21
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive. Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration. Alters endometrial development, decreasing implantation likelihood.
Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.
FDA-approved: Prevention of pregnancy.,Off-label: Treatment of acne vulgaris, regulation of menstrual disorders, dysmenorrhea.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females >= 15 years of age who have achieved menarche, are not pregnant, and desire oral contraception
One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 24 days, followed by a low-dose iron-containing tablet (75 mg ferrous fumarate) for 4 days.
One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.
Norethindrone: 5-12 hours; Ethinyl estradiol: 13-27 hours. The terminal half-life supports once-daily dosing; steady state is achieved within 5-7 days.
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours (terminal). Steady-state achieved within 3-5 days.
Ethinyl estradiol undergoes CYP3A4-mediated hydroxylation and glucuronidation; norethindrone is metabolized via reduction, glucuronidation, and sulfation, primarily by CYP3A4 and CYP2E1.
Ethinyl estradiol is metabolized primarily via CYP3A4 and undergoes glucuronidation and sulfation. Norethindrone acetate is deacetylated to norethindrone, which is metabolized by CYP3A4 and other CYP enzymes, and undergoes reduction and glucuronidation.
Ethinyl estradiol and norethindrone are primarily excreted in urine (about 50-60%) and feces (about 30-40%) as glucuronide and sulfate conjugates after hepatic metabolism.
Biliary/fecal (40-50% as metabolites) and renal (30-40% as glucuronide and sulfate conjugates)
Norethindrone: ~97% bound, primarily to sex hormone-binding globulin (SHBG) and albumin. Ethinyl estradiol: ~97% bound, primarily to albumin and SHBG.
Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 95-97% bound to albumin and SHBG.
Norethindrone: approximately 3.6 L/kg; Ethinyl estradiol: approximately 2.7 L/kg. Large Vd indicates extensive tissue distribution (reproductive organs, liver, fat).
Ethinyl estradiol: 2.5-4.5 L/kg; norethindrone: 3.5-5.5 L/kg. Indicates extensive tissue distribution.
Norethindrone: approximately 64% (oral) due to first-pass metabolism. Ethinyl estradiol: approximately 55% (oral) due to first-pass metabolism and intestinal conjugation.
Ethinyl estradiol: 38-48% (oral, first-pass metabolism); norethindrone acetate: 50-70% (oral, deacetylation to norethindrone).
No dosage adjustment required for mild to moderate renal impairment. Not recommended for use in patients with severe renal impairment or end-stage renal disease due to lack of data.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure.
Contraindicated in patients with hepatic disease, including acute hepatitis, hepatic adenomas, or cirrhosis. No dose adjustment recommendations; avoid use.
Contraindicated in acute hepatitis, severe cirrhosis, benign or malignant liver tumors, or Child-Pugh class C cirrhosis. Use with caution in Child-Pugh class A or B; consider alternative therapy.
Approved for use in postmenarchal females. Dosage same as adults: one active tablet daily for 24 days followed by iron-containing tablets for 4 days. Not indicated for premenarchal females.
Not indicated for use before menarche. Post-menarche: same dosing as adults; use lowest effective dose for shortest duration.
Not indicated for use in postmenopausal women. No specific dosing recommendations; therapy should be discontinued if menopause occurs.
Not indicated for postmenopausal women; no established dosing in elderly. Consider alternative therapies as necessary.
Cigarette smoking increases risk of serious cardiovascular events (thrombosis, myocardial infarction, stroke) from combination oral contraceptives, especially in women over 35 who smoke >15 cigarettes/day.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age (especially in women > 35 years) and with the number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
Thrombotic disorders, hypertension, gallbladder disease, hepatic neoplasia, retinal thrombosis, carbohydrate/lipid effects, headache, menstrual irregularities, depression, hereditary angioedema.
Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction), especially in smokers and women over 35,Hepatic neoplasia (benign and malignant) reported,Hypertension and gallbladder disease,Carbohydrate and lipid effects; monitor in diabetic patients,Ocular lesions (e.g., retinal thrombosis); discontinue if unexplained vision loss or proptosis occurs,Hereditary angioedema exacerbation,Chloasma; avoid sun exposure,Menstrual irregularities (e.g., breakthrough bleeding, amenorrhea),Depression; discontinue if severe
Thrombophlebitis/thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected pregnancy, undiagnosed abnormal genital bleeding, known/suspected breast cancer, hepatic tumors (benign/malignant), hypersensitivity to any component, smoking >15 cigarettes/day in women >35 years.
Thrombophlebitis, thromboembolic disorders, or history thereof (e.g., deep vein thrombosis, pulmonary embolism),Cerebrovascular disease (e.g., stroke, TIA),Coronary artery disease (e.g., myocardial infarction, angina),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Benign or malignant liver tumors,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35 years of age
No specific food interactions. Grapefruit juice may increase ethinyl estradiol levels; avoid excessive consumption. Alcohol does not affect efficacy but may worsen side effects like nausea or dizziness. The ferrous fumarate in placebo pills may be absorbed better with vitamin C (e.g., orange juice).
No specific food interactions. Grapefruit juice may increase estrogen exposure (mild effect). Maintain consistent timing with meals to reduce nausea if needed. Avoid alcohol if liver function is compromised.
First trimester: Postmarketing studies have not shown an increased risk of birth defects with oral contraceptives. Second and third trimesters: Contraindicated due to potential adverse effects on fetal development including possible estrogenic effects on fetal genitalia. Discontinue if pregnancy occurs.
Estrostep 21 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: increased risk of cardiovascular malformations, limb reduction defects, and neural tube defects. Second and third trimesters: associated with fetal genital abnormalities, feminization of male fetuses, and potential long-term reproductive effects. Use in early pregnancy for emergency contraception is not recommended due to potential risks.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio not established. Use may reduce milk production and composition. Not recommended during breastfeeding; consider alternative contraception.
Estrostep 21 is excreted in breast milk in small amounts; ethinyl estradiol M/P ratio approximately 0.1; norethindrone M/P ratio ~0.5. May reduce milk production and quality, especially in early lactation. Use generally avoided during breastfeeding; consider progestin-only alternatives.
No dosing adjustments are applicable as Loestrin 24 Fe is contraindicated during pregnancy. Discontinue immediately upon pregnancy confirmation.
Estrostep 21 is contraindicated in pregnancy; no dose adjustments recommended as use is avoided. Pharmacokinetic changes during pregnancy (increased hepatic metabolism, volume of distribution) would require dose adjustment if used, but due to risks, alternative therapy is indicated.
Loestrin 24 Fe contains norethindrone acetate and ethinyl estradiol with 24 active tablets and 4 ferrous fumarate placebo tablets. It is approved for contraception and acne vulgaris in women ≥16 years. The shortened hormone-free interval (4 vs 7 days) may reduce breakthrough bleeding and improve ovarian suppression. Counsel patients that the iron tablets are not active hormone and serve only to maintain routine. If a dose is missed, the patient should take the missed pill as soon as remembered and continue the remaining pills, possibly requiring backup contraception. Breakthrough bleeding is common in the first few cycles; rule out pregnancy if persistent.
ESTROSTEP 21 is a monophasic oral contraceptive containing norethindrone acetate and ethinyl estradiol. Due to its low estrogen dose (20 mcg), it may be associated with more breakthrough bleeding compared to higher-dose pills. It is indicated for contraception and may be used for acne treatment. The 21-day regimen requires a 7-day hormone-free interval. Counsel patients that smoking increases the risk of serious cardiovascular adverse effects; avoid in women over 35 who smoke.
Take one pill daily at the same time, preferably after a meal to reduce nausea.,The 4 brown pills contain iron; they are not hormonal and are taken during the placebo week.,Use backup contraception (condoms) for the first 7 days if starting for the first time or after a break.,Missing pills increases risk of pregnancy; follow package instructions for missed doses.,Do not smoke while taking this medication, especially if over 35 years old, due to increased risk of blood clots.,Report severe abdominal pain, chest pain, shortness of breath, headache, visual changes, or leg pain/swelling.,Regular gynecological exams and blood pressure monitoring are recommended.,Store at room temperature away from moisture and heat.
Take one tablet daily at the same time each day for 21 days, then no pills for 7 days.,If you miss a dose, follow the package instructions; use backup contraception if missed more than one tablet.,Do not smoke while taking this medication; smoking increases risk of blood clots, stroke, and heart attack, especially if over 35.,Common side effects include spotting, nausea, breast tenderness, and headache; these often improve after a few cycles.,Seek emergency care if you have signs of a blood clot: sudden leg pain, chest pain, shortness of breath, or vision changes.,This medication does not protect against HIV or other sexually transmitted infections.,Take missed pills as soon as remembered; do not take more than two tablets in one day.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOESTRIN 24 FE vs ESTROSTEP 21, answered by our medical review team.
LOESTRIN 24 FE is a Combined Oral Contraceptive that works by Combination estrogen-progestin contraceptive. Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration. Alters endometrial development, decreasing implantation likelihood.. ESTROSTEP 21 is a Combined Oral Contraceptive that works by Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOESTRIN 24 FE and ESTROSTEP 21 depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOESTRIN 24 FE is: One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 24 days, followed by a low-dose iron-containing tablet (75 mg ferrous fumarate) for 4 days.. The standard adult dose of ESTROSTEP 21 is: One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOESTRIN 24 FE and ESTROSTEP 21 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOESTRIN 24 FE is classified as Category C. First trimester: Postmarketing studies have not shown an increased risk of birth defects with oral contraceptives. Second and third trimesters: Contraindicated due to potential adv. ESTROSTEP 21 is classified as Category C. Estrostep 21 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: increased risk of cardiovascular malformations, limb reduction defects, and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.